Company’s first full-scale fermentation run reinforces commercial viability for a robust pipeline of Biosynthetic KSMS and APIs
At Antheia, we spend a lot of time talking about synthetic biology due to the nature of our work engineering yeast to produce key starting materials (KSMs) and active pharmaceutical ingredients (APIs) for essential medicines. However, synbio’s cousin, the long-established field of synthetic chemistry, plays a vital role. This is the third and final blog […]
Each year, SynBioBeta hosts the The Global Synthetic Biology Conference to showcase the latest cutting-edge developments in biology that are changing how we solve global problems. Antheia was a proud sponsor of this year’s event, and participated in two high impact talks designed to share our progress toward transforming pharmaceutical supply chains. In this first video, CEO […]
Brewer’s yeast engineered with synthetic biology to produce drugs or raw materials could transform pharmaceutical supply chains.
Antheia was founded in 2015 by Dr. Christina Smolke, CEO and Dr. Kristy Hawkins, CSO and is based in Menlo Park, California. Antheia’s co-founders are pioneers in the fields of synthetic biology and metabolic engineering and are applying these technologies to transform pharmaceutical supply chains in order to better support the needs of 21st century healthcare.
Each year, SynBioBeta hosts the The Global Synthetic Biology Conference to showcase the latest cutting-edge developments in biology that are changing how we solve global problems. As a proud sponsor of this year’s event, we look forward to connecting with the synthetic biology community and sharing our progress toward transforming pharmaceutical supply chains.
We continue to see the U.S. government setting policy priorities that underscore the importance of both building a robust American bioeconomy and strengthening domestic pharmaceutical supply chains – two core pillars of Antheia’s business and technology.
Synthetic chemistry is an essential part of drug development, opening the door for scientists to create complex small molecules with specific properties. Small molecule drugs – including household staples like aspirin and acetaminophen – currently make up the bulk of approved pharmaceuticals to date.
Our co-founder and CEO, Christina Smolke, was named to Forbes’ list of top ten women founders taking the synthetic biology world by storm. From her groundbreaking work at Stanford to the impressive team she has built at Antheia, Christina has been a pioneer in the synbio space and we are thrilled to see her recognized alongside an esteemed group of individuals who are unlo
At Antheia, we spend a lot of time talking about synthetic biology due to the nature of our work engineering yeast to produce active pharmaceutical ingredients (APIs) and key starting materials (KSMs)…